Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
People for the Ethical Treatment of Animals v. Doughney court ruled that Doughney violated the ACPA. However, the court further held that PETA was not entitled to damages because Doughney registered and used the domain prior to ACPA's enactment. Instead Doughney was merely required to surrender the domain. The court ruled that PETA was ineligible for an award of attorney's fees because Doughney did not maliciously infringe the trademark because he was creating a parody and had a First Amendment right to do so. People for the Ethical Treatment of Animals v. Doughney People for the Ethical Treatment of Animals v. Doughney, 263 F.3d 359 (4th Cir. 2001), was